givosiran
Sign in to saveAlso known as Givlaari, ALN-AS1
Givosiran, sold under the brand name Givlaari, is a medication used for the treatment of adults with acute hepatic porphyria. Givosiran is a small interfering RNA (siRNA) directed towards delta-aminolevulinate synthase 1 (ALAS1), an important enzyme in the production of heme.
In the Vinony graph
Within Vinony's link graph, givosiran is referenced by 54 other articles, and connects out to laronidase, Arylsulfatase B and medication.
Vinony files it under Drugs with non-standard legal status, Infobox drug articles without a structure image and Orphan drugs.
Its subject is documented across 10 Wikipedia language editions.
Medication
- Brand names
- Givlaari
- Drug class
- Various alimentary tract and metabolism products
- Active ingredients
- givosiran
- Dosage form
- Injection
Clinical Trials
6 registered- PHASE3COMPLETEDENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)Alnylam Pharmaceuticals · NCT03338816
- RECRUITINGELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)Alnylam Pharmaceuticals · NCT04883905
- PHASE1COMPLETEDA Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)Alnylam Pharmaceuticals · NCT02452372
- APPROVED_FOR_MARKETINGExpanded Access Protocol of Givosiran for Patients With Acute Hepatic PorphyriaAlnylam Pharmaceuticals · NCT04056481
- PHASE1COMPLETEDA Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)Alnylam Pharmaceuticals · NCT03505853
- PHASE1/PHASE2COMPLETEDA Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)Alnylam Pharmaceuticals · NCT02949830
~2 min read
Encyclopedic overview
4 sectionsContents
- Medical uses
- History
- References
- External links
Givosiran, sold under the brand name Givlaari, is a medication used for the treatment of adults with acute hepatic porphyria. Givosiran is a small interfering RNA (siRNA) directed towards delta-aminolevulinate synthase 1 (ALAS1), an important enzyme in the production of heme.
The most common side effects include nausea and injection site reactions.
Excerpted from Wikipedia’s “givosiran” article, available under the CC BY-SA 4.0 licence.